,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-07-24 22:23:00,"Boston Scientific ( BSX ) reported adjusted earnings per share (after considering certain adjustments other than amortization expense) (""EPS"") of 12 cents in the second quarter of 2013, a penny ahead of the year-ago adjusted EPS.",0.8887989521026611,0.060986194759607315,0.05021492391824722,positive,0.8278127312660217
1,2013-07-24 22:23:00,"However, considering the amortized expense adjustments, the quarter's adjusted EPS came in at 18 cents, beating the year-ago adjusted EPS of 17 cents.",0.9167158007621765,0.0576062873005867,0.025677915662527084,positive,0.8591095209121704
2,2013-07-24 22:23:00,This exceeds the company's adjusted EPS guidance range of 14-17 cents.,0.3517720103263855,0.03698079288005829,0.611247181892395,neutral,0.314791202545166
3,2013-07-24 22:23:00,The Zacks Consensus Estimate for the reported quarter was 16 cents.,0.022247131913900375,0.08063390105962753,0.8971189856529236,neutral,-0.05838676914572716
4,2013-07-24 22:23:00,"Revenues declined 1% year over year (up 2% at constant exchange rate or CER, excluding divested business) to $1.809 billion during the second quarter of 2013.",0.018171925097703934,0.9722131490707397,0.00961493793874979,negative,-0.9540412425994873
5,2013-07-24 22:23:00,"However, it exceeded the Zacks Consensus Estimate of $1.779 billion as well as the company provided guidance range of $1.740−$1.800 billion.",0.9188579320907593,0.03153977915644646,0.04960222914814949,positive,0.8873181343078613
6,2013-07-24 22:23:00,"The company also presented an encouraging performance in the BRIC (Brazil, Russia, India and China) nations with 29% (same at CER) sales growth during the quarter.",0.9540183544158936,0.0183373112231493,0.027644267305731773,positive,0.9356810450553894
7,2013-07-24 22:23:00,"Boston Scientific currently has three new global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.",0.07198399305343628,0.004631330259144306,0.9233846664428711,neutral,0.06735266000032425
8,2013-07-24 22:23:00,"The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions.",0.028852129355072975,0.00474511319771409,0.9664027690887451,neutral,0.024107016623020172
9,2013-07-24 22:23:00,"Sales at these sub-segments were a respective $520 million (down 3% year over year at CER) and $199 million (up 5% at CER), during the quarter.",0.03085438720881939,0.9418439865112305,0.027301594614982605,negative,-0.9109895825386047
10,2013-07-24 22:23:00,"Global sales of coronary stent system (within Interventional Cardiology) were $304 million, down 10.6% due to a disappointing performance from drug-eluting stents (""DES"") that declined 9.7% to $287 million and bare-metal stents that plunged 22.7% to $17 million.",0.01923154853284359,0.9714094400405884,0.00935900304466486,negative,-0.952177882194519
11,2013-07-24 22:23:00,"The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.",0.06994349509477615,0.005626555532217026,0.9244298934936523,neutral,0.06431694328784943
12,2013-07-24 22:23:00,This segment also continued to disappoint with a 2% decline during the reported quarter to $511 million.,0.02262192592024803,0.9658997058868408,0.011478434316813946,negative,-0.9432777762413025
13,2013-07-24 22:23:00,"Worldwide CRM revenues remained at $475 million, with a 2.7% drop in sales.",0.015539389103651047,0.9723300337791443,0.01213069912046194,negative,-0.9567906260490417
14,2013-07-24 22:23:00,"Sales from pacemakers remained flat year over year, while defibrillators declined 3.7% to $342 million.",0.018869973719120026,0.9694278240203857,0.011702227406203747,negative,-0.9505578279495239
15,2013-07-24 22:23:00,"Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments.",0.9060390591621399,0.012852884829044342,0.08110802620649338,positive,0.8931861519813538
16,2013-07-24 22:23:00,"However, the dismal performance of these segments during the reported quarter proved beyond doubt that these measures have not been enough to counter the current challenges.",0.12745526432991028,0.8345138430595398,0.03803087770938873,negative,-0.7070585489273071
17,2013-07-24 22:23:00,"Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $325 million (up 8% at CER), $124 million (up 1%) and $111 million (up 21%), respectively.",0.8762402534484863,0.017520977184176445,0.10623868554830551,positive,0.8587192893028259
18,2013-07-24 22:23:00,Gross margin grew 232 basis points (bps) year over year to 70.7%.,0.9579563140869141,0.018454749137163162,0.023588966578245163,positive,0.9395015835762024
19,2013-07-24 22:23:00,Adjusted operating margin expanded 58 bps to 19.2% in the quarter.,0.9582424759864807,0.018308712169528008,0.023448804393410683,positive,0.9399337768554688
20,2013-07-24 22:23:00,"During the reported quarter, selling, general and administrative expenses grew selling 2% to $661 million, research and development expenses increased 4.7% to $223 million and royalty expense declined 2.1% to $41 million.",0.3196365535259247,0.6334302425384521,0.04693315178155899,negative,-0.31379368901252747
21,2013-07-24 22:23:00,"Boston Scientific exited the quarter with cash and cash equivalents of $530 million, up from $207 million at the end of fiscal 2012 and had long-term debt of $4.25 billion.",0.9466158747673035,0.01792008988559246,0.035464003682136536,positive,0.928695797920227
22,2013-07-24 22:23:00,The company generated operating cash flow of $396 million and repurchased 12.5 million shares during the quarter under the existing share repurchase program.,0.31929460167884827,0.010083995759487152,0.670621395111084,neutral,0.3092105984687805
23,2013-07-24 22:23:00,Boston Scientific provided its third-quarter guidance and updated its fiscal 2013 outlook.,0.09130966663360596,0.00724139716476202,0.9014489650726318,neutral,0.08406826853752136
24,2013-07-24 22:23:00,"For the third quarter, the company expects to report adjusted EPS of 14-16 cents on revenues of $1.700−$1.860 billion.",0.216423898935318,0.02339097671210766,0.7601851224899292,neutral,0.19303292036056519
25,2013-07-24 22:23:00,"The current Zacks Consensus Estimate for EPS of 16 cents is in line with the outlook, although the same for revenues stands beyond the company's guidance at $1.715 billion.",0.5537675619125366,0.06863994151353836,0.3775924742221832,positive,0.48512762784957886
26,2013-07-24 22:23:00,"For full year 2013, the company increased its revenue guidance to the band of $7.050 to $7.170 billion (earlier $6.950 to $7.150 billion) with adjusted EPS in the range of 67−71 cents (65−70 cents previously).",0.944445788860321,0.015609987080097198,0.03994419053196907,positive,0.9288358092308044
27,2013-07-24 22:23:00,"The Zacks Consensus Estimate for revenues stands at $7.052 billion, while EPS is at 67 cents.",0.016021057963371277,0.016723940148949623,0.9672549962997437,neutral,-0.0007028821855783463
28,2013-07-24 22:23:00,"While the revenue estimate was within the company's guidance range, EPS estimate remained at the lower end.",0.08582935482263565,0.3911200761795044,0.5230505466461182,neutral,-0.30529072880744934
29,2013-07-24 22:23:00,"After several dismal quarters, Boston Scientific managed to beat estimates in the second quarter of 2013.",0.9297133088111877,0.04702126607298851,0.02326546423137188,positive,0.8826920390129089
30,2013-07-24 22:23:00,"However, challenging economic conditions, competitive environment, pressure on core segments and currency fluctuations remain major headwinds.",0.025292590260505676,0.9027597904205322,0.07194768637418747,negative,-0.8774672150611877
31,2013-07-24 22:23:00,"Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments, implantable cardioverter defibrillator and DES (contributing 35% of sales) continue to face challenges.",0.2652111351490021,0.44519492983818054,0.28959396481513977,negative,-0.17998379468917847
32,2013-07-24 22:23:00,The US defibrillator market remains an overhang for Boston Scientific and its peers.,0.11107325553894043,0.31699010729789734,0.5719366669654846,neutral,-0.2059168517589569
33,2013-07-24 22:23:00,"The DES business in the U.S. has been witnessing challenges due to pricing pressure, lower procedural volume, lower penetration rates and share losses from the launch of Medtronic 's ( MDT ) Resolute Integrity stent.",0.023452607914805412,0.955966591835022,0.02058073692023754,negative,-0.9325140118598938
34,2013-07-24 22:23:00,"However, to revive its top line, Boston Scientific is focusing on strategic initiatives to drive growth and profitability.",0.9141353964805603,0.013334576971828938,0.072530098259449,positive,0.9008008241653442
35,2013-07-24 22:23:00,"These include restructuring initiatives, strengthening of its portfolio, targeting suitable acquisitions in areas of unmet medical needs and focus on emerging markets.",0.7938192486763,0.010370687581598759,0.19581010937690735,positive,0.7834485769271851
36,2013-07-24 22:23:00,"Currently, Boston Scientific retains a Zacks Rank #4 (Sell).",0.09710901975631714,0.01225660927593708,0.8906343579292297,neutral,0.08485241234302521
37,2013-07-24 22:23:00,"Medical products companies such as HealthNet, Inc .",0.02498790994286537,0.03133585304021835,0.943676233291626,neutral,-0.006347943097352982
38,2013-07-24 22:23:00,"( HNT ) and Hospira Inc. ( HSP ), which carry a Zacks Rank #1 (Strong Buy), are worth considering.",0.4921547472476959,0.010716300457715988,0.49712884426116943,neutral,0.48143845796585083
39,2013-07-24 22:23:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
40,2013-07-24 22:23:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
